ArticleAbdominal radiology (New York)2026
Dual-layer detector spectral CT-derived extracellular volume fraction combined with clinical parameters for predicting lymphovascular and perineural invasion in gastric cancer.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study aimed to evaluate the feasibility and diagnostic performance of extracellular volume fraction (ECV), derived from iodine concentration (IC) values obtained through dual-layer detector spectral CT, in combination with clinical parameters, for preoperative prediction of lymphovascular invasion and/or perineural invasion (LVI/PNI) in gastric cancer.
methodsThis retrospective study included clinical and pathologic data of 124 patients diagnosed with GC at our hospital between September 2023 and February 2025. The patients were stratified into LVI/PNI-positive (n = 85) and LVI/PNI-negative (n = 39) groups based on their postoperative histopathologic findings. All patients underwent contrast-enhanced dual-layer detector spectral CT. Preoperative hematocrit levels were obtained, and IC values within the tumor were measured during the delayed phase. Concurrently, IC in the abdominal aorta at the same anatomical level was measured to calculate the ECV using the formula: ECV = (1 - hematocrit) × (IC_tumor / IC_blood). Clinical variables and spectral CT parameters were analyzed using univariate analysis, LASSO selection, and multivariable logistic regression to identify independent predictors of the composite LVI/PNI endpoint. The diagnostic performance of individual parameters and the combined model for preoperatively predicting vascular and neural invasion was assessed using receiver operating characteristic (ROC) curve analysis.
resultsECV, CT-N stage, and Borrmann classification were identified as independent predictors of the composite LVI/PNI endpoint in patients with GC (all P < 0.05). Among the candidate models, the combined model incorporating ECV, CT-N stage, and Borrmann classification achieved the best predictive performance, with AUCs of 0.920 in the training cohort and 0.917 in the validation cohort. DeLong analysis showed that the combined model significantly outperformed the CT-N stage model and the Borrmann classification model in both cohorts. However, its improvement over the ECV-only model was not statistically significant.
conclusionsDelayed-phase dual-layer detector spectral CT-derived ECV is a promising noninvasive biomarker for identifying the composite LVI/PNI endpoint in gastric cancer. A combined model integrating ECV, CT-N stage, and Borrmann classification provides the best overall diagnostic performance, although its incremental benefit over ECV alone appears limited.
Indexed as
Identifiers
41893908What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.